China SXT Pharmaceuticals, Inc.

Listed Company
SXTCCIK 0001723980NasdaqNon-AcceleratedPharmaceutical PreparationsD8VGFY ends Mar 31
Period
FY 2025
Revenue
Net Income
$-3.30M
Total Assets
$21.66M
Equity
$15.44M
Shares Out
3.91M
Op. Cash Flow
$-2.35M

Business

China SXT Pharmaceuticals, Inc. is an offshore holding company that conducts its business in China through subsidiaries and a variable interest entity, Taizhou Suxuantang, focusing on research, development, manufacturing, marketing and sales of traditional Chinese medicinal products (TCMP). It offers Advanced TCMP (including Directly‑Oral and After‑Soaking‑Oral formulations), Regular TCMP, and raw medicinal materials, with prior Fine TCMP offerings now discontinued. Its operations are organized through WFOE-provided technical and management services, R&D and GMP‑certified manufacturing facilities, quality control and patented processing technologies. The company primarily distributes TCMPs to hospitals, pharmaceutical distributors, wholesalers and chain pharmacies across multiple Chinese provinces (notably Jiangsu, Anhui, Jiangxi, Guangdong and Hubei) via regional sales offices and third‑party distributors.

Summary from filing dated 2025-07-31

Financials

Latest annual snapshot (FY2025, period end 2025-03-31). Full statement history unavailable for this entity.

Revenue
Net income$-3.30M
Total assets$21.66M
Total liabilities$6.22M
Stockholders' equity$15.44M
Operating cash flow$-2.35M

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro